Henry Schein double upgraded to Buy from Underperform at BofA

As previously reported, BofA analyst Allen Lutz upgraded Henry Schein (HSIC) to Buy from Underperform with a price target of $84, up from $69, telling investors that the company “stands out as a best-of-breed dental asset strategically positioned to compound EPS at healthy rates.” Anniversarying last year’s cybersecurity incident should improve headline numbers, as incremental share losses look “manageable,” says the analyst, who adds that Henry Schein is well positioned to gain share from both distributors and manufacturers.